| abstract |
The present application refers to new active-binder (ADC) conjugates of N, N-dialkylauriestatins directed towards the FGFR2 target, to effective metabolites of these ADCs, to procedures for the preparation of these ADCs, to the use of these ADCs for the treatment and / or prevention of diseases as well as the use of these ADCs for the preparation of medicaments for the treatment and / or prevention of diseases, especially hyperproliferative and / or angiogenic diseases such as cancer. Such treatments can be performed as monotherapies or also in combination with other medications or other therapeutic measures. |